Black Swan Sale

50% Off Elite

Register Now!

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

Last Close
Nov 26  •  04:00PM ET
17.58
Dollar change
+0.43
Percentage change
2.53
%
CategoryTarget Date / Multi-Asset - Other Asset TypeMulti-Asset - Tactical / Active TagsU.S. Return% 1Y-15.76% Total Holdings31 Perf Week4.71%
SponsorSimplify ETF ETF Type Tagsequity Return% 3Y- AUM80.15M Perf Month2.16%
Fund Family Bond Type Tagsbonds Return% 5Y- NAV/sh Perf Quarter9.25%
Index- Average Maturity Tagsmulti-asset Return% 10Y 52W High24.12 -27.11% Perf Half Y20.42%
Index Weighting Commodity Type Tagshealthcare Return% SI 52W Low12.71 38.37% Perf YTD14.41%
Active/Passive Quant Type Tagsbiotechnology Flows% 1M0.00% Volatility1.46% 1.85% Perf Year-21.25%
Dividend TTM2.72 (15.47%) ESG Type Tagspharmaceutical Flows% 3M1.62% ATR (14)0.36 Perf 3Y-
Dividend Ex-DateSep 25, 2025 Dividend Type Sector/Theme Flows% YTD-0.08% RSI (14)63.98 Perf 5Y-
Dividend Gr. 3/5Y- - Structure Type Region Flows% 1Y Beta1.18 Perf 10Y-
Expense2.57% Growth/Value SMA206.35% Flows% 3Y Rel Volume0.40 Prev Close17.15
Inverse/Leveraged Market Cap SMA506.72% Flows% 5Y Avg Volume3.90K Price17.58
IPOFeb 10, 2023 Option/ShortNo / Yes SMA20011.80% Trades Volume1,547 Change2.53%
Simplify Propel Opportunities ETF seeks to provide long-term growth of capital. The fund is an actively managed exchange-traded fund. The Sub-Adviser concentrates the fund's investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The fund is non-diversified.